Jonathan E. Rosenberg

Jonathan E. Rosenberg, MD is Chief of the Bladder Cancer Medical Oncology Service at Memorial Sloan Kettering Cancer Center (MSKCC), where he leads one of the world's most active programs in urothelial carcinoma research. He is internationally recognized for transformative contributions to bladder cancer treatment, including pivotal work establishing atezolizumab as the first PD-L1 inhibitor approved for urothelial carcinoma. His IMvigor210 cohort 2 trial, published in The Lancet in 2016, demonstrated durable responses to atezolizumab in platinum-refractory metastatic urothelial cancer, setting the stage for the immunotherapy era in this disease. Dr. Rosenberg is the principal investigator of EV-302 (KEYNOTE-A39), the landmark phase III trial demonstrating that enfortumab vedotin plus pembrolizumab significantly prolonged overall survival and progression-free survival compared with platinum-based chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma. Published in the New England Journal of Medicine in 2024, EV-302 established this antibody-drug conjugate plus checkpoint inhibitor combination as the new standard of care in the first-line setting and represents the most significant advance in urothelial cancer therapy in decades. Beyond these landmark trials, Dr. Rosenberg has led extensive investigations into predictive biomarkers for immunotherapy response, the biology of FGFR3 alterations, and the mechanism of action of antibody-drug conjugates in urothelial cancer. He has authored over 300 peer-reviewed publications and is a highly sought-after collaborator and mentor whose work has fundamentally reshaped clinical practice in bladder and urothelial cancer management worldwide.